In adults with non‑diabetic chronic kidney disease and persistent proteinuria (≥300 mg/day) and eGFR ≥20 mL/min/1.73 m², when should SGLT2‑inhibitor therapy be initiated, what dose is recommended, and how should the patient be monitored?

SGLT2 Inhibitors in Non-Diabetic Proteinuric CKD

For adults with non-diabetic CKD, eGFR ≥20 mL/min/1.73 m², and proteinuria ≥300 mg/day (ACR ≥200 mg/g), initiate an SGLT2 inhibitor immediately—this is a strong (1A) recommendation that reduces kidney failure, cardiovascular mortality, and all-cause mortality. 1

When to Initiate

The 2024 KDIGO guidelines provide clear thresholds based on proteinuria severity:

• ACR ≥200 mg/g (≥20 mg/mmol) with eGFR ≥20: Strong recommendation (1A) to initiate SGLT2i regardless of diabetes status 1
• ACR <200 mg/g with eGFR 20-45: Weaker recommendation (2B) to consider SGLT2i 1
• Heart failure present: Strong recommendation (1A) regardless of albuminuria level 1

The BMJ 2024 guideline reinforces this with risk-stratified recommendations: for patients at high or very high risk of CKD progression (which includes those with proteinuria ≥300 mg/day), SGLT2i therapy receives a strong recommendation based on moderate-to-high certainty evidence showing reductions in kidney failure, cardiovascular mortality, and all-cause mortality 2.

Dosing Recommendations

Standard dosing for CKD:

• Dapagliflozin: 10 mg once daily
• Empagliflozin: 10 mg once daily

These doses were used in the pivotal trials (DAPA-CKD, EMPA-KIDNEY) and should be maintained regardless of eGFR decline during treatment 1. The guidelines do not recommend dose titration based on kidney function—use the standard dose and continue it.

Monitoring Protocol

SGLT2i initiation does NOT require altered CKD monitoring frequency 1. This is a critical practice point that distinguishes SGLT2i from RAS inhibitors.

Expected eGFR Changes

• An initial eGFR decline (typically 2-5 mL/min/1.73 m²) within the first 2-4 weeks is expected and hemodynamically mediated—this is NOT an indication to discontinue therapy 1
• This "dip" represents restoration of tubulo-glomerular feedback and reduction in hyperfiltration 3
• After the initial dip, SGLT2i slow the rate of eGFR decline long-term (by approximately 1-2 mL/min/1.73 m² per year) 4, 5

Monitoring Schedule

Continue your standard CKD monitoring:

• Serum creatinine/eGFR: Every 3-6 months (based on CKD stage)
• Proteinuria: Every 3-6 months to assess treatment response
• Electrolytes: Standard monitoring; no specific potassium concerns with SGLT2i alone
• Volume status: Assess clinically at each visit

Safety Monitoring

Withhold SGLT2i temporarily during:

• Prolonged fasting or NPO status
• Major surgery (perioperative period)
• Critical medical illness
• Severe dehydration or volume depletion

These situations increase ketoacidosis risk 1.

Do NOT discontinue for:

• Initial eGFR decline <30% from baseline
• eGFR falling below 20 mL/min/1.73 m² after initiation (continue until dialysis starts) 1
• Mild genital mycotic infections (treat and continue SGLT2i)

Evidence Supporting Non-Diabetic Use

The evidence base is robust: a 2025 meta-analysis of 70,361 participants demonstrated SGLT2i reduce CKD progression (HR 0.62) and kidney failure (HR 0.66) regardless of baseline albuminuria or eGFR, including in those with minimal proteinuria (ACR ≤30 mg/g: HR 0.58) 5. Real-world data from 354 non-diabetic CKD patients showed eGFR slope improved from -5.6 to -1.7 mL/min/1.73 m²/year after SGLT2i initiation, independent of baseline proteinuria 4.

Common Pitfalls to Avoid

1. Don't stop for initial eGFR dip: This hemodynamic effect is expected and beneficial long-term
2. Don't wait for "optimal" conditions: Initiate when criteria are met; delays cost kidney function
3. Don't require diabetes diagnosis: The 2024 guidelines explicitly extend recommendations to non-diabetic CKD 1
4. Don't discontinue at eGFR <20: Continue until dialysis initiation unless intolerance occurs 1
5. Don't forget sick-day counseling: Educate patients to hold SGLT2i during acute illness with poor oral intake

Practical Implementation Algorithm

1. Confirm eligibility: Non-diabetic CKD + eGFR ≥20 + proteinuria ≥300 mg/day (ACR ≥200 mg/g)
2. Initiate: Dapagliflozin 10 mg or empagliflozin 10 mg daily
3. Educate: Explain expected initial eGFR dip, genital hygiene, sick-day medication rules
4. Monitor: Continue standard CKD monitoring schedule (no intensification needed)
5. Continue: Maintain therapy through eGFR decline unless dialysis initiated or intolerance develops

The strength of this recommendation reflects consistent mortality and kidney failure benefits across multiple high-quality trials, with the 2024 KDIGO guidelines representing the most current synthesis of evidence 1.